MedTrace Logo

Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC

NCT06023758 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-05-10

No results posted yet for this study

Summary

This is a multicenter II study to compare KN026 and KN046 versus Oxaliplatin, Capecitabine combined KN026 and KN046 in patients with HER2-positive locally advanced resectable gastric cancer or gastroesophageal junction adenocarcinoma.

Conditions

  • HER2-positive Locally Advanced Resectable Gastric Cancer

Interventions

DRUG

KN026

KN026：30 mg/kg Q3W

DRUG

KN046

KN046：5 mg/kg Q3W

DRUG

XELOX

Oxaliplatin 130mg/m2 d1，Capecitabine 1000mg/m2 d1-14，Q3W

Sponsors & Collaborators

  • Peking University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-22
Primary Completion
2025-09-01
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06023758 on ClinicalTrials.gov